221 related articles for article (PubMed ID: 37833074)
1. Structural insights into the complex of oncogenic KRas4B
Tariq M; Ikeya T; Togashi N; Fairall L; Kamei S; Mayooramurugan S; Abbott LR; Hasan A; Bueno-Alejo C; Sukegawa S; Romartinez-Alonso B; Muro Campillo MA; Hudson AJ; Ito Y; Schwabe JW; Dominguez C; Tanaka K
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37833074
[TBL] [Abstract][Full Text] [Related]
2. Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms.
Vigil D; Martin TD; Williams F; Yeh JJ; Campbell SL; Der CJ
J Biol Chem; 2010 Nov; 285(45):34729-40. PubMed ID: 20801877
[TBL] [Abstract][Full Text] [Related]
3. G-protein binding features and regulation of the RalGDS family member, RGL2.
Ferro E; Magrini D; Guazzi P; Fischer TH; Pistolesi S; Pogni R; White GC; Trabalzini L
Biochem J; 2008 Oct; 415(1):145-54. PubMed ID: 18540861
[TBL] [Abstract][Full Text] [Related]
4. Structures of RGL1 RAS-Association Domain in Complex with KRAS and the Oncogenic G12V Mutant.
Eves BJ; Gebregiworgis T; Gasmi-Seabrook GMC; Kuntz DA; Privé GG; Marshall CB; Ikura M
J Mol Biol; 2022 May; 434(9):167527. PubMed ID: 35257782
[TBL] [Abstract][Full Text] [Related]
5. RalGDS family members couple Ras to Ral signalling and that's not all.
Ferro E; Trabalzini L
Cell Signal; 2010 Dec; 22(12):1804-10. PubMed ID: 20478380
[TBL] [Abstract][Full Text] [Related]
6. A role for RalGDS and a novel Ras effector in the Ras-mediated inhibition of skeletal myogenesis.
Ramocki MB; White MA; Konieczny SF; Taparowsky EJ
J Biol Chem; 1998 Jul; 273(28):17696-701. PubMed ID: 9651367
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ.
Dharmaiah S; Bindu L; Tran TH; Gillette WK; Frank PH; Ghirlando R; Nissley DV; Esposito D; McCormick F; Stephen AG; Simanshu DK
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6766-E6775. PubMed ID: 27791178
[TBL] [Abstract][Full Text] [Related]
8. Ral activation promotes melanomagenesis.
Zipfel PA; Brady DC; Kashatus DF; Ancrile BD; Tyler DS; Counter CM
Oncogene; 2010 Aug; 29(34):4859-64. PubMed ID: 20562921
[TBL] [Abstract][Full Text] [Related]
9. The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions.
Nakhaeizadeh H; Amin E; Nakhaei-Rad S; Dvorsky R; Ahmadian MR
PLoS One; 2016; 11(12):e0167145. PubMed ID: 27936046
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel RalGDS-related protein as a candidate effector for Ras and Rap1.
Peterson SN; Trabalzini L; Brtva TR; Fischer T; Altschuler DL; Martelli P; Lapetina EG; Der CJ; White GC
J Biol Chem; 1996 Nov; 271(47):29903-8. PubMed ID: 8939933
[TBL] [Abstract][Full Text] [Related]
11. Involvement of phosphatidylinositol 3-kinase, but not RalGDS, in TC21/R-Ras2-mediated transformation.
Murphy GA; Graham SM; Morita S; Reks SE; Rogers-Graham K; Vojtek A; Kelley GG; Der CJ
J Biol Chem; 2002 Mar; 277(12):9966-75. PubMed ID: 11788587
[TBL] [Abstract][Full Text] [Related]
12. Thermodynamic mapping of effector protein interfaces with RalA and RalB.
Campbell LJ; Peppa M; Crabtree MD; Shafiq A; McGough NF; Mott HR; Owen D
Biochemistry; 2015 Feb; 54(6):1380-9. PubMed ID: 25621740
[TBL] [Abstract][Full Text] [Related]
13. The quaternary assembly of KRas4B with Raf-1 at the membrane.
Jang H; Zhang M; Nussinov R
Comput Struct Biotechnol J; 2020; 18():737-748. PubMed ID: 32257057
[TBL] [Abstract][Full Text] [Related]
14. Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression.
Al-Mulla F; Milner-White EJ; Going JJ; Birnie GD
J Pathol; 1999 Mar; 187(4):433-8. PubMed ID: 10398103
[TBL] [Abstract][Full Text] [Related]
15. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
[TBL] [Abstract][Full Text] [Related]
16. RalB directly triggers invasion downstream Ras by mobilizing the Wave complex.
Zago G; Veith I; Singh MK; Fuhrmann L; De Beco S; Remorino A; Takaoka S; Palmeri M; Berger F; Brandon N; El Marjou A; Vincent-Salomon A; Camonis J; Coppey M; Parrini MC
Elife; 2018 Oct; 7():. PubMed ID: 30320548
[TBL] [Abstract][Full Text] [Related]
17. Conformational resolution of nucleotide cycling and effector interactions for multiple small GTPases determined in parallel.
Killoran RC; Smith MJ
J Biol Chem; 2019 Jun; 294(25):9937-9948. PubMed ID: 31088913
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
Nussinov R; Tsai CJ; Jang H
Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632
[TBL] [Abstract][Full Text] [Related]
19. The activation of RalGDS can be achieved independently of its Ras binding domain. Implications of an activation mechanism in Ras effector specificity and signal distribution.
Linnemann T; Kiel C; Herter P; Herrmann C
J Biol Chem; 2002 Mar; 277(10):7831-7. PubMed ID: 11748241
[TBL] [Abstract][Full Text] [Related]
20. Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation.
Kidd AR; Snider JL; Martin TD; Graboski SF; Der CJ; Cox AD
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):205-12. PubMed ID: 20619549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
